Modafinil vs Tyrosine for energy
Short answer: For energy, users rate them about the same: 91% report improvement with Modafinil (307 reports) and 89% with Tyrosine (152 reports).
Modafinil has 155 meta-analyses and 297 randomized trials on PubMed; Tyrosine has 2,190 and 1,766.
Based on 1,116 reports about Modafinil and 1,154 about Tyrosine. Not medical advice.
| Modafinil Medication | Tyrosine Supplement | |
|---|---|---|
| User score | 45 | 47 |
| Verdict | Mixed | Mixed |
| Positive of reports that state an outcome | 48% | 56% |
| Reports | 1,116 | 1,154 |
| Research | AResearch: Strong | AResearch: Strong |
| Meta-analyses / RCTs | 155 / 297 | 2,190 / 1,766 |
| Mainly used for | ||
| Weight loss % reporting improvement | 100% (5) | — |
| Appetite % reporting improvement | 40% (15) | — |
| Focus % reporting improvement | 84% (454) | 82% (206) |
| Energy % reporting improvement | 91% (307) | 89% (152) |
| Sleep % reporting improvement | 19% (75) | 30% (10) |
| Anxiety % reporting improvement | 26% (73) | 60% (40) |
| Mood % reporting improvement | 62% (90) | 83% (160) |
| Memory % reporting improvement | 71% (21) | 78% (9) |
| Performance % reporting improvement | 88% (17) | 100% (8) |
| Pain & inflammation % reporting improvement | — | 50% (4) |
| Libido % reporting improvement | 33% (9) | 75% (12) |
| Hormones % reporting improvement | — | 100% (6) |
| Heart & lipids % reporting improvement | 9% (11) | — |
| Skin & hair % reporting improvement | 50% (2) | 67% (6) |
| Immunity % reporting improvement | — | 100% (2) |
| Common side effects | insomnia, anxiety, headache, tolerance | anxiety, insomnia, jitteriness, headache |
| Typical dose reported | as needed | 500 mg / daily |
Our findings represent the most comprehensive available evidence base to inform patients, families, clinicians, guideline developers, and policymakers on the choice of ADHD medications across age groups. Taking into account both efficacy and safety, evidence from this meta-analysis supports methylphenidate in children and adolescents, and amphetamines in adults, as preferred first-choice medications for the short-term treatment of ADHD. New research should be funded urgently to assess long-term effects of these drugs.
Lancet Psychiatry, 2018 ↗“It did make me focused and alert. I was working two jobs at the time and needed every ounce of energy I could muster.”
In patients with EGFR-mutated NSCLC, first and third generation EGFR tyrosine kinase inhibitors, as well as combination therapies with antiangiogenesis, were associated with increased risks of cardiovascular adverse events. Risks were significantly higher with third generation compared with first generation inhibitors.
BMJ, 2025 ↗“I stack taurine with tyrosine and creatine and that has helped my mood noticeably and also helps me feel stronger and more energetic.”
Related comparisons
Percentages come from first-hand user reports and are not clinical outcomes. Talk to a doctor before starting, stopping or combining anything. How we rate